FDA Safety Update: Dermal Fillers and Risks of Delayed Inflammation

July 28, 2023

The U.S. Food and Drug Administration (FDA) recently updated both its web page on Dermal Fillers (Soft Tissue Fillers) and on Dermal Fillers Do’s and Don’t for Wrinkles, Lips and More. A spokesperson for the FDA reported that the update was made in response to postmarketing data from the FDA’s adverse event—reporting databases, including the Manufacturer and User Facility Device Experience (MAUDE) for devices and the Vaccine Adverse Event Reporting System (VAERS) for vaccines, published literature and recommendations from federal agencies and professional societies.

“More specifically, the site was updated to include certain risks of using dermal fillers such as swelling and bruising as well as some less common risks such as inflammation—swelling or redness near the dermal filler injection site—following viral or bacterial illnesses or infections, vaccinations, or dental procedures,” the spokesperson said.

Read more at MedEsthetics >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Growth, Capital and Control: Navigating Private Equity in Aesthetics
    • Med Spas Under the Microscope – The View From The FDA
    • Revance and Teoxane Announce RHA Dynamic Volume is Now Available
    • Terri Ross Consulting Appoints Cameron Hemphill as Chief Operating Officer and Strategic Advisor
    • Galderma’s Restylane Contour Gains FDA Approval for the Correction of Temple Hollowing